Form 4: Y-mAbs Therapeutics Executive Sells Shares to Cover Tax Obligations

Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold 10,810 shares of common stock to cover tax liabilities associated with vesting restricted stock units.

Summary

• Thomas Gad, the Chief Business Officer of Y-mAbs Therapeutics, sold 10,810 shares of common stock on March 7, 2025.
• The sale was executed to cover tax liabilities associated with the vesting and settlement of restricted stock units.
• The shares were sold at a weighted average price of $5.23, with individual trades ranging from $5.15 to $5.27.
• Following the transaction, Gad directly owns 202,721 shares of Y-mAbs Therapeutics.
• Gad also indirectly owns 67,681 shares through GAD Enterprises LLC and 60,000 shares through his children.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an executive to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives and directors. The sale appears to be related to tax obligations, which is a typical reason for insider sales.

Key Dates